Emerging Therapies for the Treatment of Neovascular Age Related Macular Degeneration

REFERENCES

• Friedman DS, O’Colmain BJ, Munoz B et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004; 122(4):564–572.
   PubMedGoogle Scholar
• Congdon N, O’Colmain B, Klaver CC et al. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 2004; 122(4):477–485.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006; 355(14):1419–1431.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006; 355(14):1432–1444.
   PubMedGoogle Scholar
• Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 2004; 25(4):581–611.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer. Cell. 2007; 12(1):9–22.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Byrnes G, Sen N et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010; 30(10):1579–1587.
   PubMedGoogle Scholar
• Brugarolas J, Lei K, Hurley RL et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004; 18(23):2893–2904.
   PubMedGoogle Scholar
• Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Investig. Drugs 2007; 16(1):83–107.
   PubMedGoogle Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer. 2003; 3(6):401–410.
   PubMed Web of Science ®Google Scholar
• Holekamp NM, Bouck N, Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am. J. Ophthalmol. 2002; 134(2):220–227.
   PubMedGoogle Scholar
• Mori K, Duh E, Gehlbach P et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J. Cell. Physiol. 2001; 188(2):253–263.
   PubMedGoogle Scholar
• Mori K, Gehlbach P, Yamamoto S et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2002; 43(6):1994–2000.
   PubMedGoogle Scholar
• Campochiaro PA, Nguyen QD, Shah SM et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum. Gene Ther. 2006; 17(2):167–176.
   PubMedGoogle Scholar
• Lee MJ, Van Brocklyn JR, Thangada S et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998; 279(5356):1552–1555.
   PubMedGoogle Scholar
• Xie B, Shen J, Dong A et al. Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J. Cell. Physiol. 2009; 218(1):192–198.
   PubMedGoogle Scholar
• Heeschen C, Weis M, Aicher A et al. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J. Clin. Invest. 2002; 110(4):527–536.
   PubMedGoogle Scholar
• Kiuchi K, Matsuoka M, Wu JC et al. Mecamylamine suppresses basal and nicotine-stimulated choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2008; 49(4):1705–1711.
   PubMedGoogle Scholar
• Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264(5158):569–571.
   PubMed Web of Science ®Google Scholar
• Kim S, Bell K, Mousa SA et al. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am. J. Pathol. 2000; 156(4): 1345–1362.
   Google Scholar
• Parsons-Wingerter P, Kasman IM, Norberg S et al. Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am. J. Pathol. 2005; 167(1):193–211.
   PubMedGoogle Scholar
• Wilson SH, Ljubimov AV, Morla AO et al. Fibronectin fragments promote human retinal endothelial cell adhesion and proliferation and ERK activation through alpha5beta1 integrin and PI 3-kinase. Invest. Ophthalmol. Vis. Sci. 2003; 44(4):1704–1715.
   PubMedGoogle Scholar
• Yang JT, Rayburn H, Hynes RO Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 1993; 119(4):1093–1105.
   PubMedGoogle Scholar
• Fassler R, Meyer M. Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev. 1995; 9(15):1896–1908.
   PubMedGoogle Scholar
• George EL, Georges-Labouesse EN, Patel-King RS et al. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993; 119(4):1079–1091.
   PubMedGoogle Scholar
• Ramakrishnan V, Bhaskar V, Law DA et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J. Exp. Ther. Oncol. 2006; 5(4):273–286.
   PubMedGoogle Scholar
• Zahn G, Vossmeyer D, Stragies R et al. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch. Ophthalmol. 2009; 127(10):1329–1335.
   PubMedGoogle Scholar
• Zahn G, Volk K, Lewis GP et al. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. Invest. Ophthalmol. Vis. Sci. 2010; 51(2):1028–1035.
   PubMedGoogle Scholar
• Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125(9):1591–1598.
   PubMedGoogle Scholar
• Gee MS, Procopio WN, Makonnen S et al. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am. J. Pathol. 2003; 162(1):183–193.
   Google Scholar
• Lindahl P, Johansson BR, Leveen P et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277(5323):242–245.
   PubMed Web of Science ®Google Scholar
• Jo N, Mailhos C, Ju M et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am. J. Pathol. 2006; 168(6):2036–2053.
   PubMedGoogle Scholar
• Dark GG, Hill SA, Prise VE et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997; 57(10):1829–1834.
   PubMedGoogle Scholar
• Nambu H, Nambu R, Melia M et al. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2003; 44(8):3650–3655.
   PubMedGoogle Scholar
• Williams PB, Lattanzio FA, Jr., Grevem CM et al. OC-10X, a novel tubulin inhibitor, inhibits neovascularization in a nonhuman primate model of AMD. ARVO 2010.
   Google Scholar
• Anderson DH, Radeke MJ, Gallo NB et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin. Eye Res. 2010; 29(2):95–112.
   PubMed Web of Science ®Google Scholar
• Zarbin MA, Rosenfeld PJ. Pathway-based therapies for age-related macular degeneration: An integrated survey of emerging treatment alternatives. Retina 2010; 30(9):1350–1367.
   PubMedGoogle Scholar